Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users

Canadian Journal of Public Health

Volumn 96, Issue 5, 2005, Pages 344-347

  Collins, Courtney L C ^a   Kerr, Thomas ^a,b   Tyndall, Mark W ^a,c   Marsh, David C ^a,c,d   Kretz, Patricia S ^a   Montaner, Julio S ^a,c   Wood, Evan ^a,c  

^a ST PAUL S HOSPITAL   (Canada)

^b Canadian HIV/AIDS Legal Network   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d VANCOUVER COASTAL HEALTH   (Canada)

Author keywords

Hepatitis C; HIV; Intravenous; Substance abuse

Indexed keywords

COCAINE; ILLICIT DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANADA; CIGARETTE SMOKING; COMMUNITY CARE; DISEASE TRANSMISSION; DRUG ABUSE; DRUG CONTROL; DRUG DEPENDENCE; DRUG OVERDOSE; EVIDENCE BASED MEDICINE; HEALTH BEHAVIOR; HEALTH CARE FACILITY; HEALTH HAZARD; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MORTALITY; MOUTH DISEASE; NORTH AMERICA; PREVALENCE; PRIMARY MEDICAL CARE; PUBLIC HEALTH SERVICE; REVIEW;

EID: 26844496048     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03404029     Document Type: Review

References (54)

1. Strathdee SA, Galai N, Safaeian M, Celentano DD, Vlahov D, Johnson L, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: A 10-year perspective. Arch Intern Med 2001;161:1281-88.
2. Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CAMJ 2003;168(1):19-24.
3. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study. BMJ 1998;317(7156):433-37.
4. Thorpe LE, Ouellet LJ, Levy JR, Williams IT, Monterroso ER. Hepatitis C virus infection: Prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999. J Infect Dis 2000;182(6):1588-94. Epub 2000 Nov 2.
5. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002;155(7):645-53.
6. Selvey LA, Denton M, Plant AJ. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: Factors influencing hepatitis C serostatus. Aust N Z J Public Health 1997;21(1):102-4.
7. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatologv 2001;34(1):180-87.
8. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001;91(1):42-46.
9. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997;35(12):3274-77.
10. Tortu S, Neaigus A, McMahon J, Hagen D. Hepatitis C among noninjecting drug users: A report. Subst Use Misuse 2001;36(4):523-34.
11. Flamm SL, Parker RA, Chopra S. Risk factors associated with chronic hepatitis C virus infection: Limited frequency of an unidentified source of transmission. Am J Gastroenterol 1998;93(4):597-600.
12. Tortu S, McMahon JM, Pouget ER, Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse 2004;39(2):211-24.
13. McMahon JM, Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoactive Drugs 2003;35(4):455-60.
14. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334(26):1691-96.
15. Alter HJ, Conry-Cantilena C, Melpolder J, Tan D, Van Raden M, Herion D, et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997;26(3 Suppl 1):29S-33S.
16. Wood E, Tyndall MW, Li K, Lloyd-Smith E, Small W, Montaner JS, et al. Do supervised injecting facilities attract higher-risk injection drug users? Am J Prev Med 2005;29(2):126-30.
17. Broadhead RS, Kerr TH, Grund J-PC, Altice FL. Safer injection facilities in North America: Their place in public policy and health initiatives. J Drug Issues 2002;32(1):329-55.
18. de Jong W, Wever U. The professional acceptance of drug use: A closer look at drug consumption rooms in the Netherlands, Gemany, and Switzerland. Int J Drug Policy 1999;10:99-108.
19. Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, et al. Rationale for evaluating North America's first medically supervised safer-injecting facility. The Lancet Infectious Diseases 2004;4(5):301-6.
20. Haemmig R. Beyond safe injecting rooms: Next steps in harm reduction incl. safe smoking rooms. 15th International Conference on the Reduction of Drug Related Harm 2004, Melbourne, Australia.
21. Wood E, Kerr T, Small W, Li K, Marsh DC, Montaner JS, et al. Changes in public order after the opening of a medically supervised safer injection facility for illicit injection drug users. CMAJ 2004;171(7):731-34.
22. Wood E, Spittal PM, Small W, Kerr T, Li K, Hogg RS, et al. Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ 2004;170(10):1551-56.
23. Campbell L. 'Four Pillars - the Vancouver experience'. 15th International Conference on the Reduction of Drug Related Harm 2004, Melbourne, Australia.
24. Wood E, Kerr T, Spittal PM, Tyndall MW, O'Shaughnessy MV, Schechter MT. The healthcare and fiscal costs of the illicit drug use epidemic: The impact of conventional drug control strategies and the impact of a comprehensive approach. BCMJ 2003;45(3):130-36.
25. Sterk CE, Theall KP, Elifson KW. Who's getting the message? Intervention response rates among women who inject drugs and/or smoke crack cocaine. Prev Med 2003;37(2):119-28.
26. Rosse RB, Collins JP, Jr., Fay-McCarthy M, Alim TN, Wyatt RJ, Deutsch SI. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: A retrospective study. Clin Neuropharmacol 1994;17(4):359-69.
27. Colliver JD, Kopstein AN. Trends in cocaine abuse reflected in emergency room episodes reported to DAWN. Drug Abuse Warning Network. Public Health Rep 1991;106(1):59-68.
28. Fischer B, Rehm J, Kim G, Robins A. Safer injection facilities (SIFs) for injection drug users (IDUs) in Canada: A review and call for an evidence-focused pilot trial. Can J Public Health 2002;93(5):336-38.
29. Darke S, Ross J. Fatal heroin overdoses resulting from non-injecting routes of administration, NSW, Australia, 1992-1996. Addiction 2000;95(4):569-73.
30. Thiblin I, Eksborg S, Petersson A, Fugelstad A, Rajs J. Fatal intoxication as a consequence of intranasal administration (snorting) or pulmonary inhalation (smoking) of heroin. Forensic Sci Int 2004;139(2-3):241-47.
31. Smith C. Baffling brain ailment hits heroin smokers. Georgia Straight, January 22, 2004.
32. Centers for Disease Control. Top 11 most frequently asked questions about viral hepatitis. Available on-line at: http://www.cdc.gov/nci-dod/diseases/hepatitis/common_faqs.htm (Accessed June 15, 2004).
33. Faruque S, Edlin BR, McCoy CB, Word CO, Larsen SA, Schmid DS, et al. Crack cocaine smoking and oral sores in three inner-city neighborhoods. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13(1):87-92.
34. Porter J, Bonilla L. Crack users' cracked lips: An additional HIV risk factor. Am J Public Health 1993;83(10):1490-91.
35. Mitchell-Lewis DA, Phelan JA, Kelly RB, Bradley JJ, Lamster IB. Identifying oral lesions associated with crack cocaine use. J Am Dent Assoc 1994;125(8):1104-8, 1110.
36. Barr CE, Lopez MR, Rua-Dobles A, Miller LK, Mathur-Wagh U, Turgeon LR. HIV-associated oral lesions; immunologic, virologic and salivary parameters. J Oral Pathol Med 1992;21(7):295-98.
37. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993;269(6):729-30.
38. McCarthy GM, Mackie ID, Koval J, Sandhu HS, Daley TD. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med 1991;20(7):332-36.
39. Patton LL, van der Horst C. Oral infections and other manifestations of HIV disease. Infect Dis Clin North Am 1999;13(4):879-900.
40. Wood E, Schechter MT, Tyndall MW, Montaner JS, O'Shaughnessy MV, Hogg RS. Antiretroviral medication use among injection drug users: Two potential futures. AIDS 2000;14(9):1229-35.
41. Miller CL, Wood E, Spittal PM, Li K, Frankish JC, Brairstein P, et al. The future face of coinfection: Prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr 2004;36(2):743-749.
42. Edlin BR, Irwin KL, Faruque S, McCoy CB, Word C, Serrano Y, et al. Intersecting epidemics - crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N Engl J Med 1994;331(21):1422-27.
43. Des Jarlais DC, Friedman SR. Fifteen years of research on preventing HIV infection among injecting drug users: What we have learned, what we have not learned, what we have done, what we have not done. Public Health Rep 1998;113(Suppl 1):182-88.
44. Ronco C, Spuhler G, Coda P, Schopfer R. Evaluation for alley-rooms I, II, and III in Basel. Soc Prev Med 1996;41:S58-68.
45. Vlahov D, Fuller CM, Ompad DC, Galea S, Des Jarlais DC. Updating the infection risk reduction hierarchy: Preventing transition into injection. J Urban Health 2004;81(1):14-19.
46. Fuller CM, Vlahov D, Ompad DC, Shah N, Arria A, Strathdee SA. High-risk behaviors associated with transition from illicit non-injection to injection drug use among adolescent and young adult drug users: A case-control study. Drug Alcohol Depend 2002;66(2):189-98.
47. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-19):1-39.
48. Kelley MS, Chitwood DD. Effects of drug treatment for heroin sniffers: A protective factor against moving to injection? Soc Sci Med 2004;58(10):2083-92.
49. Des Jarlais DC, Casriel C, Friedman SR, Rosenblum A. AIDS and the transition to illicit drug injection - results of a randomized trial prevention program. Br J Addict 1992;87(3):493-98.
50. van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am J Epidemiol 1994;139(12):1153-63.
51. Chitwood DD, Comerford M, Kitner KR, Palacios W, Sanchez J. A comparison of HIV risk behaviors between new and long-term injection drug users. Subst Use Misuse 2001;36(1-2):91-111.
52. Chitwood DD, Sanchez J, Comerford M, Page JB, McBride DC, Kitner KR. First injection and current risk factors for HIV among new and long-term injection drug users. AIDS Care 2000;12(3):313-20.
53. Irwin KL, Edlin BR, Faruque S, McCoy HV, Word C, Serrano Y, et al. Crack cocaine smokers who turn to drug injection: characteristics, factors associated with injection, and implications for HIV transmission. The Multicenter Crack Cocaine and HIV Infection Study Team. Drug Alcohol Depend 1996;42(2):85-92.
54. Swift w, Maher L, Sunjic S, Doan V. Transitions between routes of heroin administration: a study of Caucasian and Indochinese heroin users in South-western Sydney, Australia. Addiction 1999;92(1):71-82.